Avalo Therapeutics (AVTX) Liabilities from Discontinued Operations (2018 - 2021)

Avalo Therapeutics (AVTX) has 4 years of Liabilities from Discontinued Operations data on file, last reported at 10000.0 in Q3 2021.

• For the quarter ending Q3 2021, Liabilities from Discontinued Operations changed N/A year-over-year to 10000.0; the trailing twelve-month figure through Sep 2021 stood at 10000.0 (changed N/A YoY), and the FY2020 full-year result was 1341000.0, down 65.54% from the prior year.
• Liabilities from Discontinued Operations for Q3 2021 stood at 10000.0, down from 98000.0 in the prior quarter.
• Across five years, Liabilities from Discontinued Operations topped out at 7549631.0 in Q4 2018 and bottomed at 10000.0 in Q3 2021.
• The 4-year median for Liabilities from Discontinued Operations is 775000.0 (2020), against an average of 2183107.17.
• The widest annual swing landed in 2019, when Liabilities from Discontinued Operations slumped 48.46%; it then slumped 65.54% in 2020.
• A 4-year view of Liabilities from Discontinued Operations shows it stood at 7549631.0 in 2018, then tumbled by 48.46% to 3891012.0 in 2019, then plunged by 65.54% to 1341000.0 in 2020, then tumbled by 99.25% to 10000.0 in 2021.
• The last three Liabilities from Discontinued Operations figures came in at 10000.0 (Q3 2021), 98000.0 (Q2 2021), and 209000.0 (Q1 2021), per Business Quant data.

Peer Comparison